Low-grade fibromyxoid sarcoma (LGFMS) is a distinctive fibroblastic neoplasm that is characterized by alternating collagenous and myxoid areas, deceptively bland spindle cell morphology, a whorling architecture, and a t(7;16) translocation involving FUS and CREB3L2. Owing to variable morphology and a lack of discriminatory markers, LGFMS can be difficult to distinguish from benign mesenchymal tumors and other low-grade sarcomas. Gene expression profiling has identified differential upregulation of the mucin 4 (MUC4) gene in LGFMS compared with histologically similar tumors. MUC4 is a transmembrane glycoprotein that functions in cell growth signaling pathways; aberrant MUC4 expression has been reported in various carcinomas. We investigated MUC4 protein expression by immunohistochemistry in LGFMS and in other soft tissue tumors to determine the potential diagnostic use of this novel marker. Whole-tissue sections of 309 tumors were evaluated: 49 LGFMSs (all with FUS gene rearrangement confirmed by fluorescence in situ hybridization), 40 soft tissue perineuriomas, 40 myxofibrosarcomas, 20 cellular myxomas, 20 solitary fibrous tumors, 20 low-grade malignant peripheral nerve sheath tumors, 20 cases of desmoid fibromatosis, 20 neurofibromas, 20 schwannomas, 20 monophasic synovial sarcomas, 20 cases of dermatofibrosarcoma protuberans, 10 myxoid liposarcomas, and 10 extraskeletal myxoid chondrosarcomas. The LGFMS cases included 7 with marked hypercellularity, 4 with prominent hemangiopericytoma-like vessels, 3 with giant collagen rosettes, 3 with epithelioid morphology, 2 with focal nuclear pleomorphism, and 2 with areas of sclerosing epithelioid fibrosarcoma. All 49 LGFMS cases (100%) showed cytoplasmic staining for MUC4, which was usually diffuse and intense. All the other tumor types were negative for MUC4, apart from 6 (30%) monophasic synovial sarcomas. In conclusion, MUC4 is a highly sensitive and quite specific immunohistochemical marker for LGFMS, and can be helpful to distinguish this tumor type from histologic mimics.
L ow-grade fibromyxoid sarcoma (LGFMS) is a fibroblastic neoplasm that typically arises in the deep soft tissues of the proximal extremities or of the trunk of young adults. 6, 15, 16, 19 Despite its deceptively bland cytomorphology, LGFMS has a tendency for a protracted clinical course that is characterized by local recurrences and late distant metastases. 13, [15] [16] [17] 19 LGFMS harbors the oncogenic chimeric fusion gene FUS-CREB3L2, or rarely FUS-CREB3L1, resulting from the translocation t(7;16) (q34;p11) or t(11;16)( p11;p11), respectively. 27, 32 In its classic form, LGFMS is composed of alternating fibrous and myxoid areas with bland spindle or stellate cells in a whorled growth pattern. 15, 16, 19 However, the morphologic spectrum of LGFMS is quite variable. "Hyalinizing spindle cell tumor with giant rosettes" is a variant of LGFMS, with prominent stromal hyalinization and collagen pseudorosettes. 5, 17, 25, 37 Occasionally, LGFMS may contain areas of hypercellularity, focal nuclear pleomorphism, epithelioid morphology, or prominent hemangiopericytoma (HPC)-like vasculature. 17, 19, 21 It has recently been shown that a subgroup of so-called sclerosing epithelioid fibrosarcomas show both morphologic and molecular overlap with LGFMS, suggesting the possibility of a close relationship between these 2 tumor types. 21, 38 Given its bland cytology and variable morphology, LGFMS can be difficult to distinguish from some benign mesenchymal tumors and other low-grade sarcomas. Immunohistochemistry (IHC) using existing markers is of limited value in differential diagnosis, as the immunoprofile of LGFMS is nonspecific. To date, epithelial membrane antigen (EMA) expression has been the most consistent finding in LGFMS, ranging from 43% to 91% in published studies. 21, 27 However, the use of EMA as a diagnostic marker for LGFMS is relatively limited, as expression of EMA is often focal in LGFMS, and EMA positivity is also observed in tumors that may mimic LGFMS, such as soft tissue perineurioma and a subset of solitary fibrous tumors, among others. Definitive diagnosis of LGFMS therefore often relies on the demonstration of t(7;16)(q34;p11) or t(11;16)(p11;p11) by conventional cytogenetics, FUS gene rearrangement by fluorescence in situ hybridization (FISH), or FUS-CREB3L2/FUS-CREB3L1 fusion transcripts by reverse transcription-polymerase chain reaction (RT-PCR).
Using global gene expression analysis, our group has recently identified differential upregulation of several genes in LGFMS compared with histologically similar tumors (Mo¨ller et al, Submitted). The mucin 4 (MUC4) gene, located on the long arm of chromosome 3 (3q29), was one of the top upregulated genes, and showed corresponding overexpression of MUC4 at the protein level. MUC4 is a high-molecular weight transmembrane glycoprotein that is normally expressed on many epithelial surfaces, including respiratory, colonic, and vaginal epithelium, where it is presumed to serve a protective role. 3, 9 MUC4 also participates in cell growth signaling through interaction with the ErbB/HER2 family of growth factor receptors and activation of downstream pathways resulting in cell proliferation and survival. 3, 7, 8, 10, 44 Aberrant expression or overexpression of MUC4 has been reported in various carcinomas, including those arising in the pancreas, bile duct, breast, colon, ovary, lung, and prostate. 1, 11, 22, 34, 36, 39 Little is known about the role of MUC4 in normal mesenchymal cells or mesenchymal tumors, although a recent study showed that MUC4 can induce transformation of mouse fibroblasts in vitro. 2 In this study, we investigated MUC4 protein expression by IHC in a well-characterized series of
LGFMSs and other soft tissue tumors to determine the potential use of MUC4 as a diagnostic marker for LGFMS.
MATERIALS AND METHODS
Cases were retrieved from the surgical pathology and consult files of Brigham and Women's Hospital, Boston, MA and from the consult files of one of the authors (C.D.M.F.). Only cases of LGFMS that were previously confirmed to have FUS gene rearrangement by FISH were included. FISH analysis was carried out on either interphase nuclei isolated from 50-mm sections of formalin-fixed paraffin-embedded tissue (when available) or on 4 mm paraffin sections, according to standard protocols. FUS rearrangement was evaluated using the Vysis LSI FUS Dual Color Break Apart Probe (Abbott Molecular, Des Plaines, IL), which contains 2 differentially labeled probes that flank the FUS gene, located on 16p11. Probes and nuclei were codenatured simultaneously, followed by hybridization and washing, according to the directions of the manufacturer (Abbott Molecular). An intact FUS locus is represented by 2 fused orange/green signals. In contrast, if an FUS rearrangement has occurred, 1 copy of the orange probe will be separated from the adjacent green probe.
Representative hematoxylin and eosin-stained slides were reviewed. IHC for EMA was previously performed on all cases of LGFMS, S100 on 48 cases, CD34 on 44 cases, glial fibrillary acidic protein (GFAP) on 23 cases, and smooth muscle actin (SMA) on 21 cases.
In total, whole-tissue sections of 309 tumors were evaluated for expression of MUC4: 49 LGFMS, 40 soft tissue perineuriomas, 40 myxofibrosarcomas (17 low grade, 19 intermediate grade, and 4 high grade), 20 cellular myxomas, 20 solitary fibrous tumors, 20 lowgrade malignant peripheral nerve sheath tumors, 20 cases of desmoid fibromatosis, 20 neurofibromas, 20 schwannomas, 20 monophasic synovial sarcomas [all previously confirmed to harbor t(X;18)], 20 cases of dermatofibrosarcoma protuberans (DFSP), 10 myxoid liposarcomas, and 10 extraskeletal myxoid chondrosarcomas. One tumor that originally was thought to represent a soft tissue perineurioma was excluded from the study groups due to equivocal FISH results.
IHC was performed after pressure cooker antigen retrieval (0.01 M citrate buffer, pH 6.0) using a mouse anti-MUC4 monoclonal antibody (1:500; 8G7; Santa Cruz Biotechnology, Santa Cruz, CA) on 4-mm-thick formalin-fixed paraffin-embedded tissue sections. Appropriate positive (normal colonic epithelium) and negative controls were used throughout the study. The extent of immunoreactivity was graded according to the percentage of positive tumor cells (0, no staining; 1+, <5%; 2+, 5% to 25%; 3+, 26% to 50%; 4+, 51% to 75%; and 5+, 76% to 100%), and the intensity of staining was graded as weak, moderate, or strong.
RESULTS

Clinicopathologic Characteristics of the LGFMS Study Group
The 49 LGFMS cases affected 23 male patients and 26 female patients. The mean age was 37 years (range, 5 to 80 y). The most common anatomic site was the lower limb/buttock (n = 15), followed by the upper limb (n = 10), head and neck (n = 8), trunk (n = 6), groin/ perineum (n = 4), retroperitoneum (n = 2), lung (n = 2), mesentery (n = 1), and superior mediastinum (n = 1). One of the 2 patients with lung tumors had a known primary gluteal LGFMS; no information about the primary site was available for the other patient with a lung tumor, which was presumed to be a metastasis. All tumors were deep seated, apart from 1 tumor that arose on the thigh and involved the subcutis and dermis.
The tumors predominantly showed classic features of LGFMS, being composed of sharply demarcated collagenous and myxoid areas ( Fig. 1A) with bland spindle and stellate cells (Fig. 1C ) in a whorled or occasionally more fascicular growth pattern. Three cases contained giant collagen rosettes ( Fig. 1E) . Unusual histologic features were present in a subset of cases, including 7 cases with areas of marked hypercellularity ( Fig. 2A ), 4 with prominent HPC-like vessels (Fig. 3A ), 3 with focally epithelioid morphology (Fig. 2C ), and 2 with focally marked nuclear pleomorphism. Two cases showed areas of sclerosing epithelioid fibrosarcoma ( Fig. 4 ). In 1 of these cases, the majority of the tumor was composed of sclerosing epithelioid fibrosarcoma, with only limited areas of classic LGFMS.
EMA expression was observed in 37 of 49 (75%) cases and was usually focal. Focal positivity for CD34 was present in 3 of 44 (7%) cases and SMA in 1 of 21 LGFMS composed of bland spindle and stellate cells in a whorled growth pattern within a myxoid stroma (C). Tumor cells show strong cytoplasmic staining for MUC4 (D). A hyalinized collagen rosette surrounded by tumor cells with roundto-epithelioid morphology (E). MUC4 staining is most intense in the epithelioid tumor cells (F).
(5%) cases. Cases of LGFMS were consistently negative for S100 and GFAP.
MUC4 Expression in LGFMS and Other Soft Tissue Neoplasms
The results of IHC for MUC4 are summarized in Table 1 . All 49 LGFMS cases (100%) showed cytoplasmic staining for MUC4, which was usually diffuse (5+ in 47 cases; 4+ in 1 case; 3+ in 1 case) and intense (strong in 42 cases; moderate in 6 cases; weak in 1 case) ( Figs.  1-4) .
All other tumor types were negative for MUC4, apart from 6 (30%) monophasic synovial sarcomas, which showed predominantly focal staining (4+ strong in 1 case; 2+ strong in 1 case; 1+ strong in 1 case; 1+ moderate in 2 cases; 1+ weak in 1 case) ( Fig. 5 ).
DISCUSSION
LGFMS is a relatively recently described sarcoma type, the first 2 cases of which were reported by Evans 15 in 1987. Three larger series describing the characteristic clinicopathologic features followed shortly thereafter, supporting the existence of LGFMS as a distinct entity. 12, 16, 19 LGFMS typically arises in the deep soft tissues of the proximal extremities or of the trunk of young adults, and shows no sex predilection. 6, 15, 16, 19 In our study, the mean patient age was 37 years, and tumors were most common in the extremities (51%), followed by the head and neck (16%) and trunk (12%). FUS-CREB3 chimeric fusion genes are characteristic of LGFMS. In a study by Mertens et al 27 , the FUS-CREB3L2 fusion was found in 22 of 23 (96%) cases, whereas FUS-CREB3L1 was identified in 1 of 23 (4%) cases. The FUS-CREB3L2 fusion gene may result from a balanced translocation t(7;16)(q34;p11), more complex rearrangements involving 7q and 16p, or may be present within supernumerary ring chromosomes. 4, 28, 32, 33 To date, the translocation t(7;16)(q34;p11), or in rare cases t(11;16)(p11;p11), has been shown to be specific for LGFMS. 32 Hyalinizing spindle cell tumor with giant rosettes was first described in 1997, and, due to striking overlap in both clinical and pathologic features with LGFMS, it was proposed that the 2 tumors were related. 17, 25 This was confirmed in subsequent studies that showed the presence of t(7;16)(q34;p11) and FUS-CREB3L2 fusion in cases of both hyalinizing spindle cell tumor with giant rosettes and LGFMS. 5, 37, 40 Giant rosettes were present in 3 of 49 (6%) cases in our study. Furthermore, it has recently been shown that some cases of sclerosing epithelioid fibrosarcoma show both morphologic and molecular overlap with LGFMS, suggesting that a subgroup of these tumors may be related to LGFMS. 37, 38 Our study group included 2 cases of LGFMS with areas morphologically indistinguishable from sclerosing epithelioid fibrosarcoma (Fig. 4) . In 1 case, this morphologic pattern was extensive. Both tumors contained areas of classic LGFMS and showed FUS gene rearrangement by FISH.
Although LGFMS is usually a relatively hypocellular tumor composed of uniform, bland short spindle cells, occasional cases show variations in cytomorphology and cellularity. Two large series of LGFMS reported areas of high cellularity in 16% to 33% of cases, nuclear enlargement and hyperchromasia in 16% of cases, and areas of epithelioid change in 27% to 45% of cases. 17, 21 Other unusual morphologic features include prominent HPC-like vasculature, rich networks of curvilinear capillaries, and deposition of keloidal collagen fibers. 16, 17, 19, 21 In our study, 7 of 49 (14%) LGFMS cases contained areas of marked hypercellularity and 3 of 49 (6%) contained clusters of epithelioid cells, in 1 case appearing almost carcinoma-like (Fig. 2C) . Prominent HPC-like blood vessels were seen in 4 of 49 cases, resembling solitary fibrous tumor (Fig. 3A ). An additional 2 cases showed focally marked nuclear pleomorphism.
LGFMS may resemble some benign soft tissue tumors (eg, soft tissue perineurioma, cellular myxoma, neurofibroma, solitary fibrous tumor); soft tissue tumors with potential for locally aggressive behavior (eg, desmoid fibromatosis); and sarcomas (eg, low-grade malignant peripheral nerve sheath tumor, low-grade myxofibrosarcoma, myxoid DFSP, and, rarely, extraskeletal myxoid chondrosarcoma or synovial sarcoma with prominent myxoid stroma). 6, 13, 15, 17, 32 Low-grade myxofibrosarcoma is often confused with LGFMS, mainly as a result of their similar names. In contrast to LGFMS, low-grade myxofibrosarcoma typically arises in the subcutis of older adults, is characterized by prominent curvilinear vessels and a greater degree of nuclear atypia and hyperchromasia, and lacks the sharply demarcated alternating fibrous and myxoid areas seen in LGFMS. 31 However, the presence of focal nuclear pleomorphism or curvilinear vessels in LGFMS may result in difficulty distinguishing between these 2 tumor types.
Despite advances in the characterization of the molecular profile of LGFMS, the IHC findings are relatively nonspecific. The first IHC studies of LGFMS showed that most tumor cells were strongly positive for A B the nonspecific marker vimentin. 18, 19 Since then, EMA expression has been the most consistent IHC finding, being present in 43% to 91% of cases. 21, 27 However, EMA is also detected in tumors that may mimic LGFMS, including soft tissue perineurioma, synovial sarcoma, a subset of solitary fibrous tumors, and rare cases of DFSP, among others. 23, 26, 35 A recent study reported CD99 expression in 93% and bcl-2 in 88% of LGFMS cases. 21 However, these 2 markers are relatively ubiquitous in soft tissue tumors, and, in particular, are often positive in synovial sarcomas and solitary fibrous tumors. 20, 35 Focal positivity for SMA, desmin, CD34, and/or cytokeratin is rarely seen in LGFMS, 19, 21, 27 and S100, GFAP, caldesmon, and c-kit are typically negative. 19, 21, 32, 37 In our study, EMA expression was present in 75% of tumors, whereas CD34 and SMA were rarely positive (7% and 5% of cases, respectively). Definitive diagnosis of LGFMS therefore often relies on the demonstration of FUS gene rearrangement by FISH or detection of the FUS-CREB3L2 fusion by RT-PCR. Global gene expression profiling of LGFMS has identified differential upregulation of the MUC4 gene in LGFMS when compared with histologically similar tumors, and a similar pattern of overexpression of This pathway of discovery of a diagnostically useful biomarker is analogous to the identification of DOG1 (discovered on GIST) overexpression in gastrointestinal stromal tumors 14, 30, 43 and TLE1 (transducin-like enhancer of split) in synovial sarcomas. 24, 41 We found that 100% of a large cohort of LGFMS cases (all with FUS gene rearrangement confirmed by FISH) showed cytoplasmic expression of MUC4. Staining for MUC4 was usually diffuse: 47 of 49 (96%) cases showed positivity for MUC4 in >75% of tumor cells. Furthermore, the intensity of staining was strong in 42 of 49 (86%) cases, moderate in 6 (12%) cases, and weak in only 1 (2%) case. Interestingly, the intensity of staining was greatest in areas with epithelioid morphology (Fig. 2D ) and sclerosing epithelioid fibrosarcoma (Fig.  4D ). All other tumor types examined were negative for MUC4, apart from 6 of 20 (30%) monophasic synovial sarcomas.
Soft tissue perineurioma is a benign nerve sheath tumor with a peak incidence in young to middle-aged adults, which is composed of elongated spindle cells with slender nuclei and long bipolar cytoplasmic processes. 23 Soft tissue perineurioma may mimic LGFMS, as the tumor cells have bland morphology, often grow in a whorled pattern, and may show myxoid change. Although soft tissue perineuriomas are nearly always positive for EMA, expression of EMA is also found in a high percentage of LGFMS cases. Perineuriomas may also express CD34, claudin-1, and SMA, which are rarely positive in LGFMS. 21, 42 As expression of MUC4 was not seen in the 40 soft tissue perineuriomas evaluated in this study, MUC4 may be helpful to distinguish LGFMS from soft tissue perineurioma. It should be noted that 1 tumor not included in the final study groups, which was originally thought to represent a soft tissue perineurioma, was positive for MUC4. However, FISH for FUS rearrangement showed equivocal findings, and the case was therefore excluded from the study owing to the uncertain diagnosis.
Interestingly, 30% of monophasic synovial sarcomas showed focal expression of MUC4. This finding may reflect the epithelial differentiation inherent to synovial sarcoma. In practice, monophasic synovial sarcoma rarely enters the morphologic differential diagnosis with LGFMS, and, as such, the presence of MUC4 expression in a subset of synovial sarcomas is unlikely to be a significant diagnostic pitfall. Furthermore, demonstration of positivity for keratins and TLE1 by IHC 24, 29 t(X;18) by FISH or RT-PCR can help confirm the diagnosis of synovial sarcoma. Aberrant expression of MUC4 is thought to play a pathogenetic role in various carcinomas, whereas the role of MUC4 in the pathogenesis of LGFMS and the relationship, if any, between MUC4 overexpression and the FUS-CREB3L2 fusion gene is unknown.
In summary, global gene expression analysis of LGFMS has led to the discovery of a diagnostically useful biomarker through the identification of upregulation of the MUC4 gene. MUC4 is a highly sensitive and quite specific IHC marker for LGFMS and can be helpful to distinguish this tumor type from histologic mimics.
